Several reports showed that a combined targeted therapy, with both BRAF and MEK inhibitor agents, seems to have a better efficacy in terms of tumor volume reduction and rapidity of actions than a single BRAF inhibitor [16,17,18,19,20,22,23,25,58,59]. Here, MAP2K7 is linked to neoplasm.